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Background/Aims: Febrile neutropenia (FN) interferes with the proper chemo-
therapy dose density or intensity in non-Hodgkin’s lymphoma (NHL) patients. 
Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone 
(CHOP) ± rituximab has an intermediate FN risk. Prophylactic granulocyte col-
ony-stimulating factor (G-CSF) support is recommended for patients with other 
host-related risk factors. 
Methods: We evaluated the risk factors for FN-related admission in NHL patients 
who have received primary G-CSF (lenograstim) prophylaxis. 
Results: Data from 148 patients were analyzed. The incidence of neutropenic fe-
ver was 96 events (12.2%), and the median period was 3.85 days (range, 0 to 5.9); 
the median duration of neutropenia was 4.21 days (range, 3.3 to 5.07). Eighty-three 
FN-related admissions were reported. Advanced age (> 60 years), female sex, a low 
albumin level, and prednisone use were associated with FN-related admission in 
multivariable analysis (p = 0.010, p < 0.001, and p = 0.010, respectively). A compar-
ison between diffuse large B-cell lymphoma patients treated with R-CHOP and 
pegylated G-CSF and those treated with R-CHOP and lenograstim did not reveal 
significant differences in the FN-related admission rate between the two groups, 
although the lenograstim-treated group had a higher incidence of severe neutro-
penia. 
Conclusions: Elderly patients, female patients, and patients with low albumin 
levels need to be actively followed-up for FN even when primary prophylaxis with 
G-CSF has been used. 
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INTRODUCTION 
Even though a large proportion of non-Hodgkin’s 
lymphoma (NHL) patients could achieve a complete 
response, chemotherapy-induced febrile neutropenia 
(FN) is a major barrier to the completion of the planned 
chemotherapy. FN is frequently responsible for hospi-
tal admission, prolonged hospitalization, and imme-
diate administration of intravenous (IV) antibiotics [1]. 
It is also associated with increased infection-related 
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mortality, with an overall FN-related mortality of 6.8% 
to 20% [2,3]. Moreover, it can preclude the delivery of 
the intended dose of chemotherapeutic agents, inter-
fere with its schedule, or even lead to discontinuation of 
chemotherapy. Decreasing the dose density or intensity 
can adversely affect the treatment outcome in NHL [4]. 
Prevention of chemotherapy-related FN is the most im-
portant supportive care for improving treatment out-
comes in NHL patients. Therefore, the identification of 
high-risk patients is of primary relevance in prevention. 
Although granulocyte colony-stimulating factor (G-CSF) 
support can help reduce FN-related early deaths and 
achieve the planned dose and schedules, some patients 
still experience serious FN-related complications [5,6]. 
The American Society of Clinical Oncology and the 
European Organization for Research and Treatment of 
Cancer recommend primary prophylaxis with G-CSF 
with a chemotherapy regimen of ≥ 20% FN risk or reg-
imens with intermediate FN risk (10% to 20%), wherein 
the overall risk takes into consideration the patient-re-
lated risks [7,8]. The FN risk for cyclophosphamide, 
doxorubicin, vincristine and prednisone (CHOP)-21 
± rituximab chemotherapy was reported as 17% to 
50% [7,9], which classifies it as intermediate risk. As pre-
viously mentioned, patient-related risk factors should 
be assessed when using intermediate-risk chemothera-
py to assure that prophylactic G-CSF is provided to pa-
tients with an overall high risk. 
Based on the National Comprehensive Cancer Net-
work guideline, advanced age (≥ 65 years), previous ex-
posure to chemotherapy or radiotherapy, persistent 
neutropenia, bone marrow involvement of the tumor, 
poor performance status, recent surgery and/or open 
wounds, renal or liver dysfunction, and human immu-
nodeficiency virus infection are considered high-risk 
patient-related factors [10,11]. Among the high-risk 
patients treated with prophylactic G-CSF, identifying 
vulnerable populations for FN-related complications is 
clinically useful for FN prevention and management. 
In this study, we evaluated the FN-related outcomes, 
including FN-related admission, in NHL patients with 
high-risk patient-related factors treated with CHOP-21 
± rituximab and prophylactic G-CSF, to identify the pre-
dictive factors for FN-related admission. 
METHODS 
Patients
We enrolled 158 patients who were diagnosed with NHL 
between 2012 and 2015. Ten patients withdrew their con-
sent; therefore, data from 148 patients were analyzed. All 
patients were scheduled to receive frontline CHOP or 
R-CHOP chemotherapy. All patients were aged over 20 
years and had one or more of the following patient-re-
lated factors for FN: age ≥ 65 years, Ann Arbor stage ≥ III, 
previous chemotherapy or radiation therapy, bone mar-
row involvement, absolute neutrophil count (ANC) < 1.5 
× 109/L or hemoglobin level < 12.0 g/dL before starting 
chemotherapy, active infection, open wounds, Eastern 
Cooperative Oncology Group performance status ≥ 2 
or poor nutritional status, hepatic or renal dysfunction, 
chronic obstructive pulmonary disease, cardiovascular 
disease, and diabetes mellitus. 
Chemotherapy
All patients were treated with CHOP ± R chemotherapy 
every 3 weeks. Chemotherapy was composed of cyclo-
phosphamide (750 mg/m2 IV on day 1), doxorubicin (50 
mg/m2 IV on day 1), vincristine (1.4 mg/m2 up to 2 mg, IV 
on day 1), prednisone (100 mg oral on day 1 to 5), and rit-
uximab (375 mg/m2 IV on day 1). The treatment response 
was assessed based on the revised International Work-
shop Criteria [12]. The relative dose intensity (RDI) was 
calculated as the ratio of the actual dose intensity to the 
planned dose intensity for a fixed time period [6,9,13]: 
RDI = actual dose intensity / planned dose intensity; ac-
tual dose intensity = actual dose received for each agents 
(mg/m2) / actual duration of chemotherapy for all agents 
(days); planned dose intensity = planned total dose for 
each agent (mg/m2) / planned duration of chemotherapy 
for all agents (days). Any adverse event was assessed by 
the National Cancer Institute-Common Terminology 
Criteria for Adverse Events, 2009 (version 4.0).
Study drug
Lenograstim (Neutrogin, JW Pharmaceutical Corp., 
Seoul, Korea) is a recombinant human G-CSF. For pro-
phylaxis, 5 μg/kg/day of lenograstim was injected subcu-
taneously from days 4 to day 6 after chemotherapy and 
was continued until the ANC reached 3.0 × 109/L. In case 
of outpatients, G-CSF was administered on weekdays 
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only, while it was administered continuously without 
interruption to hospitalized patients. FN was defined 
as a single oral temperature ≥ 38.3°C or a temperature ≥ 
38.0°C sustained for > 1 hour with an ANC < 0.5 × 109/L 
or < 1.0 × 109/L predicted to fall below 0.5 × 109/L within 
48 hours [14,15]. 
 
Statistical analysis
The primary endpoint of this study was admission as-
sociated with FN during chemotherapy. The secondary 
endpoints were the development of severe neutropenia 
(defined as ANC < 0.5 × 109/L), duration of neutropenia 
(defined as ANC < 0.5 × 109/L or ANC < 1.0 × 109/L), pres-
ence and duration of FN, the incidence and duration of 
infection, use of IV antibiotics, admission not related to 
FN, reduction of dose density or intensity, complete re-
sponse rate, and progression-free survival (PFS) or over-
all survival (OS). PFS was defined as the time from the 
study enrollment to the date of disease progression or 
death from any cause. OS was calculated as the time from 
the study enrollment to death from any cause or the last 
follow-up. Treatment outcomes of lenograstim-treated 
patients were compared with those of pegylated G-CSF 
treated patients, which were obtained from the histori-
cal records. We retrieved the data of patients who com-
pleted R-CHOP chemotherapy and received pegylated 
G-CSF between 2014 and 2019. To adjust for the distri-
bution of baseline characteristics, we matched age, sex, 
and the international prognostic index. Propensity score 
matching was performed using a 1:1 matching protocol 
without replacement. Survival analysis and comparisons 
were performed using the Kaplan-Meier method and 
the log-rank test. A logistic regression model was used 
to calculate odds ratios (ORs) and 95% confidence in-
tervals (CIs). A p value < 0.05 was considered statistically 
significant for all analyses. All statistical analyses were 
performed using SPSS for Windows version 24.0 (IBM 
Corp., Armonk, NY, USA) and R package version 3.4.4 (R 
Foundation for Statistical Computing, Vienna, Austria). 
Ethical statement
The study protocol was approved by the Institutional 
Review Board of each participating institution (Sever-
ance Hospital IRB No. 4-2011-0432). Informed consent 
was obtained from all individual participants included 
in the study. 
RESULTS
Patients’ characteristics
Baseline characteristics are shown in Table 1. Median 
age was 69 years (range, 24 to 83) with 89 (60.1%) male 
patients. All patients had at least one risk factor for FN 
before chemotherapy: four (2.7%), previous chemother-
apy; two (1.4%), previous radiation; 14 (9.5%), bone mar-
row involvement at diagnosis; 4 (2.7%), low ANC (< 1.5 
× 109/L); 63 (42.6%), hemoglobin level below 12.0 g/dL, 
34 (23.0%), low albumin level (< 3.5 g/dL); four (2.7%), in-
fections; one (0.7%), open wound; eight (5.4%), renal im-
pairment; 14 (9.5%), hepatic disease; one (0.7%), chronic 
obstructive pulmonary disease; 37 (25.0%), cardiovascu-
lar disease; 23 (15.5%), diabetes mellitus; 43 (29.1%), hy-
Table 1. Baseline characteristics 
Variable No. of patients (%)
Age, yr 
≤ 60 51 (34.5)


















Low intermediate 27 (18.2)
High intermediate 39 (26.4)
High 32 (21.6)
ECOG, Eastern Cooperative Oncology Group; LDH, lactate 
dehydrogenase; IPI, international prognostic index.
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pertension; 12 (8.1%), hepatitis; and seven (4.7%), history 
of tuberculosis. 
Treatment outcomes 
Median follow-up duration was 10.0 months (range, 0 
to 38). The OS was 84.0% and PFS was 74.0% at 1-year. 
Among the 109 patients who completed the planned 
chemotherapy, 86 (78.9%) achieved complete response, 
14 (12.8%) achieved partial response, five (4.6%) had sta-
ble disease, and four (3.7%) had progressive disease. The 
Table 2. Predictive factors for FN-associated admission in the lenograstim-treated group 
Univariable analysis Odd ratio 95% CI p value
Age > 60 years 2.761 1.215–6.273 0.015a
Female sex 4.947 2.365–10.352 < 0.001a
ECOG > 2 1.120 0.366–3.454 0.843
Stage III/IV 1.232 0.615–2.467 0.600
Extranodal involvement > 1 site 1.417 0.709–2.829 0.324
Elevated LDH 1.426 0.705–2.886 0.323
Body surface area 5.050 0.698–37.037 0.108
Bone marrow involvement 1.244 0.401–3.862 0.706
Previous chemotherapy/radiotherapy 1.493 0.342–6.522 0.594
Active infection 0.807 0.082–7.970 0.855
Renal dysfunction 1.233 0.295–5.153 0.775
Hepatic dysfunction 0.874 0.263–2.902 0.827
Chronic obstructive lung disease NA
Cardiovascular disease 2.064 0.965–4.415 0.062
Anemia < 12.0 g/dL 1.268 0.636–2.526 0.500
Low albumin 2.625 1.271–5.421 0.009a
Neutropenia < 1.5 × 109/L NA
Lymphopenia < 1 × 109/L 1.977 0.811–4.826 0.134
Rituximab use 0.607 0.219–1.678 0.336
RDI-cyclophosphamide 0.100 0.013–0.773 0.027a
RDI-doxorubicin 0.152 0.021–1.123 0.065
RDI-vincristine 0.611 0.119–3.123 0.554
RDI-prednisone 0.031 0.003–0.354 0.005a
Multivariable analysis
Age > 60 years 4.925 1.681–14.435 0.004a
Female sex 5.747 2.341–14.084 < 0.001a
Low albumin 3.073 1.244–7.587 0.015a
FN, febrile neutropenia; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; 
NA, not available; RDI, relative dose intensity.
aStatistically significant.
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RDIs of the chemotherapeutic agents were as follows: 
rituximab 0.95 (0.38 to 1.02), cyclophosphamide 0.89 (0.32 
to 1.18), doxorubicin 0.86 (0.34 to 1.02), vincristine 0.73 
(0.27 to 1.05), and prednisone 0.96 (0.20 to 1.35). Through-
out the chemotherapy cycles, in total, 775 G-CSF were 
administered and the median number of G-CSF used 
was 5 per cycle (range, 1 to 30). 
Safety
The safety profiles of lenograstim were assessed by ad-
verse events. These results were assessed as secondary 
endpoints. Severe neutropenia (ANC < 0.5 × 109/L) was 
observed in 322 events among the 786 chemotherapy 
cycles, and the median duration of neutropenia was 
4.21 days (range, 3.3 to 5.07). The incidence of FN was 
96 events (12.2%); the median duration of FN was 3.85 
days (range, 0 to 5.9). The number of cases of FN-relat-
ed infection was 103; 95 patients received IV antibiotics, 
and the median duration of IV antibiotics was 8.5 days 
(range, 7.2 to 15). In total, 90 admissions were reported, 
of which 83 were related to FN, while the rest were due 
to general weakness, and infection without neutropenia, 
among other causes. 
Predictive factors for FN-related admission
The primary endpoint of this study was FN-associated 
admission during chemotherapy. The total number of 
FN-associated admissions was 83 (10.5%) among 786 cy-
cles of chemotherapy. Three factors were significantly 
associated with FN-related admission on multivariable 
analysis (Table 2): advanced age (> 60 years) (OR, 2.761; 
95% CI, 1.1215 to 6.273; p = 0.015), female sex (OR, 4.947; 
95% CI, 2.365 to 10.352; p < 0.001), and low albumin level 
(OR; 2.625; 95% CI, 1.271 to 5.421; p = 0.009). Other risk 
factors such as poor performance status (p = 0.843), ad-
vanced disease stage (p = 0.600), extranodal involvement 
at more than one site (p = 0.324), elevated lactic dehy-
drogenase levels (p = 0.323), lymphopenia < 1 × 109/L (p 
= 0.134), and the use of rituximab (p = 0.336) were not 
related with FN-associated admission. Among patients 
who received R-CHOP chemotherapy, advanced age (> 
60 years) (OR, 4.730; 95% CI, 1.468 to 15.241; p = 0.009) and 
female sex (OR, 3.782; 95% CI, 1.506 to 9.501; p = 0.005) 
were predictive factors for FN-related admission. 
Comparison with pegylated G-CSF-treated patients
A total of 97 patients were included in each group using 
propensity score matching (Table 3). The total number 
of FN-related admissions was not different between the 
two groups (47 events in the lenograstim group and 37 
events in the pegylated G-CSF-treated group; p = 0.451). 
The incidence of severe neutropenia was 39.3% (226 
events of 575 cycles) in the lenograstim-treated group 
and 18.5% (105 events among 567 cycles) in the pegylated 
G-CSF-treated group (p < 0.001). The duration of neu-
tropenia during the first cycle was 4.59 days in the le-
nograstim-treated group and 2.78 days in the pegylated 
G-CSF-treated group (p < 0.001). Other secondary end-
points were not different (Table 4). 
OS rate was 98.0% in the lenograstim-treated group 
and 94.0% in the control group at 1 year (p = 0.535) (Fig. 
1A). PFS rate was 89.0 % in lenograstim-treated group 
Table 3. Baseline characteristics in each group of patients after propensity score matching
Variable Lenograstim Pegylated filgrastim p value
Age, yr, median (range) 65 (24–83) 65 (24–86) 0.238
Sex, male/female 36/61 35/62 0.999
ECOG 0–1/≥ 2 89/8 92/5 0.568
Stage I or II/ III or IV 49/48 51/46 0.886
Extranodal involvement 0–1/> 1 58/39 69/28 0.131
LDH, normal/elevated 41/56 45/52 0.665
IPI 
Low/low intermediate 39/15 32/17 0.696
High intermediate/high 26/17 26/22
ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; IPI, international prognostic index.
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and 87.0% in the pegylated G-CSF-treated group at 1 
year (p = 0.198) (Fig. 1B). The RDI of rituximab, cyclo-
phosphamide, doxorubicin, and vincristine were high-
er in the pegylated G-CSF-treated group (p = 0.001, p = 
0.001, p < 0.001, and p < 0.001); the RDI of prednisone 
was not different (p = 0.422). 
 
DISCUSSION 
This multicenter prospective observational study eval-
uated the FN-related outcomes of primary G-CSF sup-
port in patients who received CHOP ± R chemotherapy. 
The primary endpoint of this study was the FN-related 
admission rate, which was found to be 10.5%. Advanced 
age, female sex, and low albumin levels were associated 
with FN-related admission. Compared with pegylated 
G-CSF-treated patients as a historical control, primary 
prophylaxis with lenograstim showed non-inferior FN 
related admission rate, although the incidence of severe 
neutropenia was higher in the lenograstim group. 
The chemotherapy regimen, patient-related factors, 
and tumor type and burden should be considered as 
the risk factors for FN [10]. All enrolled patients had at 
least one patient-related risk factor for FN, and we eval-
uated the predictive factors for FN-associated admis-
Table 4. Secondary endpoints of each group of patients after propensity score matching
Variable Lenograstim Pegylated filgrastim p value
FN-related admission 47 38 0.451
Severe neutropenia 226/575 105/567 < 0.001
Duration of neutropenia (1st cycle), day 4.59 2.78 < 0.001
Incidence of FN 51 47 0.776
Duration of FN (1st cycle), day 4.37 (3.11–5.92) 3.0 (1.0–5.5) 0.171
Microbial infection 1 7 0.065
IV antibiotics 44 46 0.495
Duration of IV antibiotics (1st cycle), day 8.58 (7.25–15) 8.0 (7.0–11.0) 0.176
Number of admissions 61 66 0.227
Values are presented as median (range).
FN, febrile neutropenia; IV, intravenous.
Figure 1. (A) Overall survival (OS) and (B) progression-free survival (PFS) of patients according to the type of granulocyte colo-





























Kim YR, et al. Risk factor for neutropenic fever in NHL
www.kjim.orghttps://doi.org/10.3904/kjim.2020.206
sion among these patients. The incidence of FN was 96 
events of 786 cycles (12.2%), and the FN-related admis-
sion rate was 10%. This value was lower than that previ-
ously reported [7,9]. Among lymphoma patients treated 
with CHOP-like chemotherapy without primary G-CSF 
prophylaxis, the FN-related admission rate was reported 
to be 17% to 50% [9,16]. Prophylactic G-CSF initiated in 
the first chemotherapy cycle was associated with a 0.84-
time lower risk of FN [5]. The most common adverse 
reaction to G-CSF administration was musculoskeletal 
pain, which could be managed with analgesics [17]. In 
this study, toxicity was mainly related to chemotherapy. 
Age ≥ 65 years, low albumin level, neutropenia, pres-
ence of hepatic disease, planned average RDI > 80%, and 
no early G-CSF use increased the initial hospitalization 
rate [9]. We used prophylactic G-CSF support in all high-
risk patients; however, advanced age, low albumin level, 
and female sex still had statistical significance with re-
spect to FN-related admission. The RDI of rituximab, 
cyclophosphamide, and prednisone were risk factors 
for FN-related admission on univariable analysis but it 
failed to show statistical significance on multivariable 
analysis. 
Age is an established risk factor for FN, and advanced 
age has been related to serious complications, including 
death [18-20]. The cut-off value for age is usually 65 years, 
although 60 years has been used in some reports [21]. In 
this study, 60 years of age was a significant risk factor for 
FN that requires admission. Albumin levels have been 
known to be related to FN and reflect the nutritional sta-
tus of cancer patients [22]. Female sex is also a predictive 
factor for FN [9,17]. Advanced age, female sex, and low 
albumin level led to a 4.9-, 5.7-, and 3.0- times increase 
in the risk for FN-related admission in patients with 
prophylactic support, respectively. Therefore, more ag-
gressive approaches and supportive care are needed to 
prevent FN-related admission in patients with these risk 
factors. 
After propensity score matching, there were no dif-
ferences in FN-related admissions between the le-
nograstim and pegylated G-CSF groups. Although the 
incidence of severe neutropenia was higher in the le-
nograstim group, this could be because blood test was 
not done regularly in pegylated G-CSF group. Response 
rate was not different between the groups, although the 
chemotherapy RDI was higher in the pegylated G-CSF 
group. Pegylated G-CSF could be superior in maintain-
ing a consistent dose density, and observation that needs 
further investigation. Finally, long-term follow-up is re-
quired to reveal the relation between dose density and 
treatment outcome. Previous studies revealed that four 
single doses of filgrastim are equivalent to pegylated fil-
grastim in terms of maintaining the dose intensity of 
an R-CHOP regimen administered every 2 weeks [23,24]. 
According to this study, a daily dose of 5 μg/kg lenogras-
tim until ANC recovery or one dose of 6 mg pegylated 
G-CSF can work as treatment options for NHL patients 
with patient-related risk factors.
This study has some limitations. We used daily G-CSF 
for NHL patients instead of pegylated G-CSF, which is 
now widely used for primary prophylaxis with CHOP ± 
R chemotherapy for NHL. At the beginning of the study, 
prophylactic pegylated G-CSF was not widely used in 
Korea. Moreover, it was usually used for secondary pro-
phylaxis after neutropenia development. Therefore, we 
compared the efficacy of daily primary prophylactic use 
of G-CSF and prophylactic use of pegylated G-CSF us-
ing propensity score matching from historical control. 
Furthermore, the follow-up period was not sufficiently 
long, and there was no relation between dose intensity 
and treatment outcome. Long-term follow-up is need-
ed to elucidate this issue. This study was significant in 
terms of determining the predictive factors for FN-relat-
ed admission in high-risk patients who receive CHOP-
21 ± R chemotherapy and primary prophylactic G-CSF 
support. Most importantly, the final goal of R-CHOP 
chemotherapy in diffuse large B-cell lymphoma was 
not palliative but curative; therefore, reducing the infec-
tion-related complications during chemotherapy is very 
important. 
In conclusion, this study showed the FN-related out-
comes of primary G-CSF prophylaxis in NHL patients 
with high-risk patient-related factors. Patients with ad-
vanced age, female sex, or low albumin levels before che-
motherapy should be managed cautiously to minimize 
the risk of FN-related admission despite early primary 
prophylactic G-CSF support. 
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